# Natera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/natera

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.natera.com
- Total disclosed funding: $181M
- Latest round: Series G (Apr 6, 2015)
- Investors on record: 14

## About

Natera, Inc. specializes in advanced cell-free DNA testing, providing innovative diagnostic solutions for personalized healthcare. Their tests aid in disease detection and risk assessment across various medical fields.Natera, Inc. was founded in 2004 and is headquartered in San Carlos, US. The company focuses on developing and providing noninvasive tests utilizing cell-free DNA technology. Jonathan Sheena is one of the founders, and the company has undergone significant growth since its inception. Natera has completed 16 deals, with their latest funding round being a Private Placement/Follow on in April 2019, raising USD 250.00 mn, which marks the total amount raised by the company at USD 250.00 mn.Natera offers a range of diagnostic solutions centered around cell-free DNA testing. Their primary products include noninvasive tests such as the Signatera residual disease test and the Panorama noninvasive prenatal test. These solutions are utilized in oncology, women's health, and organ health, effectively identifying disease risks and monitoring treatment responses. Natera caters to healthcare providers and patients across North America, Europe, and parts of Asia.In 2024, Natera reported a revenue of USD 1,696.91 mn, with an EBITDA of USD -191.32 mn for the same year.Natera aims to expand its product offerings with new innovations in cell-free DNA testing, targeting a broader market by 2025. The recent funding from the Private Placement/Follow on will support the launch of these upcoming products and enhance their market presence, focusing on regions including Europe and Asia. Natera's strategic initiatives include strengthening partnerships with healthcare providers and increasing accessibility to their diagnostic tests.

## Funding rounds

- Series G, Apr 6, 2015, $56M — OrbiMed Advisors, Sofinnova Investments, HealthCor Group, Jennison Associates, Capital Research and Management, RA Capital Management, Franklin Templeton
- Series F, Nov 20, 2014, $56M — Sofinnova Investments
- Series E, May 1, 2013, $28M — Lightspeed Venture Partners, OrbiMed Advisors, Hong Shan, Founders Fund, Claremont Creek Ventures, Alafi Capital, Huntington Reproductive Center, Harmony Partners
- Series D, Jan 5, 2012, $20M — Lightspeed Venture Partners, Hong Shan, Claremont Creek Ventures
- Series C, Nov 1, 2010, $12M — Lightspeed Venture Partners, Hong Shan, Founders Fund, Claremont Creek Ventures
- Series B, Jan 7, 2009, $6M — Hong Shan, Claremont Creek Ventures, Alafi Capital
- Series A, Dec 5, 2007, $4M — Hong Shan, Claremont Creek Ventures, Huntington Reproductive Center

## Investors

- Hong Shan — Series A, Series B, Series C, Series D, Series E
- Claremont Creek Ventures (https://capitalatlas.ai/funds/claremont-creek-ventures) — Series A, Series B, Series C, Series D, Series E
- Huntington Reproductive Center — Series A, Series E
- Alafi Capital (https://capitalatlas.ai/funds/alafi-capital) — Series B, Series E
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series C, Series D, Series E
- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Series C, Series E
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series E, Series G
- Harmony Partners (https://capitalatlas.ai/funds/harmony-partners) — Series E
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series F, Series G
- HealthCor Group (https://capitalatlas.ai/funds/healthcor-group) — Series G
- Jennison Associates — Series G
- Capital Research and Management — Series G
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series G
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series G